Stocks in News: Barrick Gold Corporation (NYSE:ABX), Sorrento Therapeutics (NASDAQ:SRNE), Potlatch Corporation (NASDAQ:PCH), General Growth Properties (NYSE:GGP), Achillion Pharmaceuticals (NASDAQ:ACHN)

On Thursday shares of Barrick Gold Corporation (NYSE:ABX) closed at $11.29. Company’s sales growth for last 5 years was 4.70% and EPS growth for next 5 years is recorded as 13.40%. On March 24, Barrick Gold Corporation (NYSE:ABX) announced that as per the Chilean Environmental Court’s ruling, the Pascua-Lama project has not damaged glaciers within the project’s area of influence. As per Barrick, it is essential to protect the glaciers from any harm that can be caused from its work at the Pascua-Lama project. Hence, the company worked with leading independent experts and glaciologists to develop and implement one of the most rigorous glacier monitoring programs anywhere in the world. The program captures data from 27 points and provides results directly to regulatory authorities.

Sorrento Therapeutics, Inc. (NASDAQ:SRNE) in last trading activity advanced 0.59% to close at $11.85. Company weekly performance is -15.36% while its quarterly performance stands at 39.25%. Sorrento Therapeutics, Inc. (NASDAQ:SRNE) is -22.55% away from its 52 week high. On March 19, NantWorks and Sorrento Therapeutics Inc. (NASDAQ:SRNE) have entered into a binding agreement for the discovery and development of new anti-cancer immunotherapies. The new products will be developed from Sorrento’s G-MAB library against neoepitopes of tumor-specific antigens discovered using NantWorks’ pan-omics based, precision medicine approach.

On last trading day Potlatch Corporation (NASDAQ:PCH) moved down -0.48% to close at $39.67. Its volatility for the week is 1.74% while volatility for the month is 1.58%. PCH’s sales growth for past 5 years was 5.00% and its EPS growth for past 5 years was 1.50%. Potlatch Corporation (NASDAQ:PCH) monthly performance is 0.30%. On March 20, it was reported that, A seasonal guest worker program critical to Potlatch Corporation (NASDAQ:PCH) and other Idaho forest products firms is back on track this week, after a bureaucratic dispute threatened to delay spring tree-planting efforts. Mark Benson, vice president of public affairs for the company, said Potlatch intends to plant about 6 million seedlings this year. The work is done by immigrant guest workers permitted through the H-2B visa program.

General Growth Properties, Inc (NYSE:GGP) has 1.40% insider ownership while its institutional ownership stands at 86.90%. In last trading activity company’s stock closed at $29.62. On March 20, it was reported that, General Growth Properties, the No. 2 mall operator in the country, agreed to buy some Macerich properties from Simon if it were to strike a deal. Simon said it partnered with General Growth to avoid taking on too much debt. The disposals could also help Simon avoid antitrust scrutiny in the event a deal went through. Although General Growth remained free to make an offer for all of Macerich if it chose, Macerich and its advisers said that the agreement between Simon and General Growth potentially violated antitrust laws, and depressed the potential sale price for Macerich.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) in last trading activity fell -1.67% to close at $10.00. Company weekly performance is -12.43% while its quarterly performance stands at -15.54%. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) is -40.72% away from its 52 week high. On March 18, 2015, Dr. Gautam Shah, the Executive Vice President and Chief Regulatory Officer of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) provided notice of his departure from the Company effective March 31, 2015. Subject to Dr. Shah executing a release of all claims against the Company and its affiliates, Dr. Shah will be entitled to receive benefits pursuant to the terms of his employment agreement dated April 5, 2011. Dr. Shah will continue to be subject to the terms of a Non-Competition and Non-Solicitation Agreement and a Non-Disclosure and Assignment of Inventions Agreement previously entered into with the Company.

Leave a Reply

Your email address will not be published. Required fields are marked *

*